专题：Biosimilars and Bioanalytical Methods

This cluster of papers focuses on the immunogenicity of biosimilar therapeutics, including the validation of bioanalytical methods for assessing immunogenicity, the impact of manufacturing changes on immunogenicity, and the clinical outcomes and safety of switching from reference biologics to biosimilars. The use of dried blood spots for bioanalysis and the regulatory considerations for biosimilars are also prominent topics within this cluster.
最新文献
Analysis of drug consumption and expenditure of WHO essential medicines for cancer in 40 countries and regions between 2012 and 2022: a multinational drug use study

article Full Text OpenAlex

Hematologic and lymphatic disorders associated with chimeric antigen receptor T-cell therapy: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database

article Full Text OpenAlex

Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact

article Full Text OpenAlex

Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens

article Full Text OpenAlex

Enzymes in secondary pharmacology screening panels: is there room for improvement?

review Full Text OpenAlex

Assay-Based Machine Learning: Rethinking Evaluation in Drug Discovery

preprint Full Text OpenAlex

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

article Full Text OpenAlex

<b>Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab</b>

article Full Text OpenAlex

Microplanning in high-quality vaccination: Potential and barriers experienced by multipliers

article Full Text OpenAlex

Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems

review Full Text OpenAlex

近5年高被引文献
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

article Full Text OpenAlex 1128 FWCI240.073

Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design

review Full Text OpenAlex 456 FWCI24.751

FDA approves 100th monoclonal antibody product

review Full Text OpenAlex 426 FWCI14.448

The past, present, and future of antibiotics

review Full Text OpenAlex 395 FWCI15.467

Biopharmaceutical benchmarks 2022

article Full Text OpenAlex 319 FWCI31.834

Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future

review Full Text OpenAlex 270 FWCI5.417

Targeted Drug Delivery — From Magic Bullet to Nanomedicine: Principles, Challenges, and Future Perspectives

review Full Text OpenAlex 261 FWCI10.046

How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment

review Full Text OpenAlex 236 FWCI12.89

Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning

article Full Text OpenAlex 236 FWCI30.632

A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions

review Full Text OpenAlex 222 FWCI13.841